Invivyd Inc (IVVD)

$1.36 -0.02 (-1.45%)
Market Cap 390.27M
Revenue (ttm) 53.43M
Net Income (ttm) -52.49M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -98.24%
Debt to Equity Ratio 0.00
Volume 1,361,900
Avg Vol 2,786,118
Day's Range N/A - N/A
Shares Out 282.80M
Stochastic %K 6%
Beta 0.73
Analysts Strong Sell
Price Target $10.00

Company Profile

Invivyd, Inc., together with its subsidiaries, engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States. The company offers Pemivibart, a half-life extended investigational monoclonal antibody for the pre-exposure prophylaxis prevention of COVID-19 in adults and adolescents through injection under the PEMGARDA brand. It also develops VYD2311, a monoclonal antibody, which is in Phase...

Industry: Biotechnology
Sector: Healthcare
Phone: 781 819 0080
Address:
209 Church Street, New Haven, United States
trader2sde
trader2sde Apr. 30 at 9:38 AM
$IVVD https://nypost.com/2026/04/29/opinion/miranda-devine-the-biden-admins-covid-vaccine-cover-up-and-lies-can-no-longer-be-denied-or-the-damage-it-caused/
0 · Reply
trader2sde
trader2sde Apr. 30 at 9:34 AM
$IVVD
0 · Reply
Stonky_Mcprofitface
Stonky_Mcprofitface Apr. 30 at 12:40 AM
$IVVD *cough*
1 · Reply
trader2sde
trader2sde Apr. 29 at 4:32 AM
$IVVD
0 · Reply
trader2sde
trader2sde Apr. 29 at 4:30 AM
$IVVD https://nypost.com/2026/04/28/us-news/pressure-on-doj-to-prosecute-anthony-fauci-grows-after-adviser-indictedwith-days-left-to-charge-covid-lies/
0 · Reply
trader2sde
trader2sde Apr. 28 at 5:17 PM
$IVVD https://www.cdc.gov/cfa-qualitative-assessments/php/data-research/season-outlook25-26.html
0 · Reply
trader2sde
trader2sde Apr. 28 at 5:04 PM
$IVVD when will FAUCI (pre pardoned by sleepy Joe) be behind bars?? https://www.zerohedge.com/covid-19/top-fauci-advisor-david-morens-charged-covid-records-cover-doj FDA should have gone MABS vs vaccines....
0 · Reply
trader2sde
trader2sde Apr. 28 at 1:59 PM
$IVVD
0 · Reply
trader2sde
trader2sde Apr. 28 at 1:58 PM
$IVVD https://www.medscape.com/viewarticle/long-covid-linked-brain-changes-cognitive-decline-2026a1000dhe?form=fpf
0 · Reply
trader2sde
trader2sde Apr. 28 at 1:57 PM
$IVVD
0 · Reply
Latest News on IVVD
Invivyd Announces Chairman Marc Elia to Speak at POLITICO Health Care Summit

Apr 20, 2026, 7:01 AM EDT - 10 days ago

Invivyd Announces Chairman Marc Elia to Speak at POLITICO Health Care Summit

Invivyd Stock Surges As FDA Alignment Boosts COVID-19 Program

Apr 9, 2026, 10:07 AM EDT - 20 days ago

Invivyd Stock Surges As FDA Alignment Boosts COVID-19 Program

Invivyd Transcript: Study update

Apr 9, 2026, 8:30 AM EDT - 21 days ago

Invivyd Transcript: Study update

Invivyd Announces REVOLUTION Program Progress and Advancement of Novel, Potential First- and Best-in-Class Measles Monoclonal Antibody Candidate VMS063 for Treatment and Prevention of Measles

Apr 9, 2026, 7:01 AM EDT - 21 days ago

Invivyd Announces REVOLUTION Program Progress and Advancement of Novel, Potential First- and Best-in-Class Measles Monoclonal Antibody Candidate VMS063 for Treatment and Prevention of Measles

Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apr 6, 2026, 7:01 AM EDT - 24 days ago

Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Invivyd Announces Presentation at the World Vaccine Congress Washington

Mar 30, 2026, 4:05 PM EDT - 4 weeks ago

Invivyd Announces Presentation at the World Vaccine Congress Washington

Invivyd Earnings Call Transcript: Q4 2025

Mar 5, 2026, 8:30 AM EST - 7 weeks ago

Invivyd Earnings Call Transcript: Q4 2025

Invivyd Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Recent Business Highlights and DECLARATION Clinical Trial Updates

Mar 5, 2026, 7:03 AM EST - 2 months ago

Invivyd Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Recent Business Highlights and DECLARATION Clinical Trial Updates

Invivyd Appoints Distinguished Physician and Scientist, Michael Mina, M.D., Ph.D. as Chief Medical Officer

Mar 5, 2026, 7:01 AM EST - 2 months ago

Invivyd Appoints Distinguished Physician and Scientist, Michael Mina, M.D., Ph.D. as Chief Medical Officer

Invivyd to Host Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update Conference Call on March 5, 2026

Mar 2, 2026, 4:10 PM EST - 2 months ago

Invivyd to Host Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update Conference Call on March 5, 2026

New Publication Demonstrates Variant-Agnostic Correlate of Protection from COVID-19 for Invivyd Monoclonal Antibody, Useful for Understanding of and Confidence in COVID-19 Antibodies

Feb 24, 2026, 7:01 AM EST - 2 months ago

New Publication Demonstrates Variant-Agnostic Correlate of Protection from COVID-19 for Invivyd Monoclonal Antibody, Useful for Understanding of and Confidence in COVID-19 Antibodies

Invivyd Aligns with the U.S. FDA on LIBERTY, a Phase 3 Trial to Evaluate the Safety of VYD2311 Antibody Versus mRNA COVID Vaccine, and to Characterize the Safety and Immunology of Antibody and Vaccine Co-Administration

Feb 3, 2026, 7:01 AM EST - 3 months ago

Invivyd Aligns with the U.S. FDA on LIBERTY, a Phase 3 Trial to Evaluate the Safety of VYD2311 Antibody Versus mRNA COVID Vaccine, and to Characterize the Safety and Immunology of Antibody and Vaccine Co-Administration

Invivyd and SPEAR Study Group Announce Plan for Phase 2 Study of VYD2311 for Treatment of Long COVID and COVID Vaccine-Injured Individuals to Commence Mid-2026

Jan 20, 2026, 7:01 AM EST - 3 months ago

Invivyd and SPEAR Study Group Announce Plan for Phase 2 Study of VYD2311 for Treatment of Long COVID and COVID Vaccine-Injured Individuals to Commence Mid-2026

Invivyd Reports Preliminary Fourth Quarter 2025 Revenue and Recent Business Highlights

Jan 8, 2026, 7:01 AM EST - 4 months ago

Invivyd Reports Preliminary Fourth Quarter 2025 Revenue and Recent Business Highlights

Invivyd Earns Fast Track Designation for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID

Dec 23, 2025, 7:05 AM EST - 4 months ago

Invivyd Earns Fast Track Designation for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID

Invivyd Announces Initiation of DECLARATION Clinical Trial, a Phase 3 Placebo-Controlled Pivotal Study of VYD2311, a Vaccine-Alternative Antibody to Prevent COVID

Dec 23, 2025, 7:01 AM EST - 4 months ago

Invivyd Announces Initiation of DECLARATION Clinical Trial, a Phase 3 Placebo-Controlled Pivotal Study of VYD2311, a Vaccine-Alternative Antibody to Prevent COVID

Invivyd Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 2, 2025, 2:35 PM EST - 5 months ago

Invivyd Transcript: Evercore ISI 8th Annual HealthCONx Conference

Invivyd to Participate at the 8th Annual Evercore Healthcare Conference

Nov 25, 2025, 7:01 AM EST - 5 months ago

Invivyd to Participate at the 8th Annual Evercore Healthcare Conference

Invivyd Announces Selection of Potential Best-In-Class RSV Antibody Candidate VBY329; Targeting 2H 2026 IND Readiness

Nov 24, 2025, 7:01 AM EST - 5 months ago

Invivyd Announces Selection of Potential Best-In-Class RSV Antibody Candidate VBY329; Targeting 2H 2026 IND Readiness

Helmerich and Payne, Invivyd, Home Depot And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

Nov 18, 2025, 8:23 AM EST - 5 months ago

Helmerich and Payne, Invivyd, Home Depot And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

HD HP

Invivyd Announces Pricing of $125 Million Public Offering of Common Stock and Pre-Funded Warrants

Nov 17, 2025, 10:40 PM EST - 5 months ago

Invivyd Announces Pricing of $125 Million Public Offering of Common Stock and Pre-Funded Warrants

Invivyd Announces Proposed Public Offering of Common Stock

Nov 17, 2025, 4:01 PM EST - 5 months ago

Invivyd Announces Proposed Public Offering of Common Stock

Invivyd Earnings Call Transcript: Q3 2025

Nov 6, 2025, 8:30 AM EST - 6 months ago

Invivyd Earnings Call Transcript: Q3 2025

Invivyd Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Nov 6, 2025, 7:01 AM EST - 6 months ago

Invivyd Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Invivyd to Host Third Quarter 2025 Financial Results and Corporate Update Call on November 6, 2025

Nov 3, 2025, 4:01 PM EST - 6 months ago

Invivyd to Host Third Quarter 2025 Financial Results and Corporate Update Call on November 6, 2025

Invivyd Transcript: Study Update

Oct 30, 2025, 8:30 AM EDT - 6 months ago

Invivyd Transcript: Study Update

Invivyd to Host Webcast on the REVOLUTION Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID

Oct 28, 2025, 7:01 AM EDT - 6 months ago

Invivyd to Host Webcast on the REVOLUTION Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID

Invivyd Announces U.S. IND Clearance and Alignment with U.S. FDA on Pivotal Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID

Oct 6, 2025, 7:01 AM EDT - 7 months ago

Invivyd Announces U.S. IND Clearance and Alignment with U.S. FDA on Pivotal Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID

Invivyd Appoints Paul B. Bolno, M.D.

Sep 24, 2025, 4:01 PM EDT - 7 months ago

Invivyd Appoints Paul B. Bolno, M.D.

Invivyd Announces Appointment of Kristie Kuhl as Chief Communications Officer

Sep 17, 2025, 7:01 AM EDT - 8 months ago

Invivyd Announces Appointment of Kristie Kuhl as Chief Communications Officer

Invivyd Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 8, 2025, 12:00 PM EDT - 8 months ago

Invivyd Transcript: H.C. Wainwright 27th Annual Global Investment Conference

SPEAR Study Group to Present its Recommended Long COVID Antibody Study Design Featuring Invivyd's VYD2311 At RECOVER-TLC Workshop September 9-10, 2025

Sep 4, 2025, 7:01 AM EDT - 8 months ago

SPEAR Study Group to Present its Recommended Long COVID Antibody Study Design Featuring Invivyd's VYD2311 At RECOVER-TLC Workshop September 9-10, 2025

Invivyd Transcript: Cantor Global Healthcare Conference 2025

Sep 3, 2025, 2:10 PM EDT - 8 months ago

Invivyd Transcript: Cantor Global Healthcare Conference 2025

Invivyd to Participate in Upcoming Investor Conferences

Aug 27, 2025, 7:01 AM EDT - 8 months ago

Invivyd to Participate in Upcoming Investor Conferences

Invivyd Announces Closing of $57.5 Million Public Offering and Full Exercise of the Underwriter's Option to Purchase Additional Shares

Aug 22, 2025, 12:00 PM EDT - 8 months ago

Invivyd Announces Closing of $57.5 Million Public Offering and Full Exercise of the Underwriter's Option to Purchase Additional Shares

Invivyd Announces Pricing of $50 Million Public Offering of Common Stock and Pre-Funded Warrants

Aug 20, 2025, 11:58 PM EDT - 9 months ago

Invivyd Announces Pricing of $50 Million Public Offering of Common Stock and Pre-Funded Warrants

Invivyd Announces Continued Neutralizing Activity of PEMGARDA® (pemivibart) and VYD2311 Against Currently Dominant SARS-CoV-2 Variant XFG (“Stratus”)

Aug 18, 2025, 4:32 PM EDT - 9 months ago

Invivyd Announces Continued Neutralizing Activity of PEMGARDA® (pemivibart) and VYD2311 Against Currently Dominant SARS-CoV-2 Variant XFG (“Stratus”)

Invivyd Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Aug 14, 2025, 4:49 PM EDT - 9 months ago

Invivyd Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Invivyd Aligns with U.S. FDA on Rapid Pathway to Full Approval (BLA) of Vaccine Alternative Monoclonal Antibody VYD2311 to Protect American Adults and Adolescents from COVID-19

Aug 14, 2025, 4:47 PM EDT - 9 months ago

Invivyd Aligns with U.S. FDA on Rapid Pathway to Full Approval (BLA) of Vaccine Alternative Monoclonal Antibody VYD2311 to Protect American Adults and Adolescents from COVID-19

Scientist Dr. Akiko Iwasaki Joins SPEAR Study Group to Investigate Monoclonal Antibodies for Long COVID and COVID-19 Post-Vaccination Syndrome

Jul 23, 2025, 7:01 AM EDT - 10 months ago

Scientist Dr. Akiko Iwasaki Joins SPEAR Study Group to Investigate Monoclonal Antibodies for Long COVID and COVID-19 Post-Vaccination Syndrome

National Comprehensive Cancer Network® (NCCN®) Guidelines Recommend Monoclonal Antibodies for COVID-19 Prevention in People with Cancer; New Data Published in JAMA Oncology Underscore Severe Impact of COVID-19 on This Population

Jul 21, 2025, 7:05 AM EDT - 10 months ago

National Comprehensive Cancer Network® (NCCN®) Guidelines Recommend Monoclonal Antibodies for COVID-19 Prevention in People with Cancer; New Data Published in JAMA Oncology Underscore Severe Impact of COVID-19 on This Population

Invivyd and Leading Researchers Form SPEAR (Spike Protein Elimination and Recovery) Study Group to Assess the Effects of Monoclonal Antibody Therapy for Long COVID and COVID-19 Post-Vaccination Syndrome

Jul 2, 2025, 7:01 AM EDT - 10 months ago

Invivyd and Leading Researchers Form SPEAR (Spike Protein Elimination and Recovery) Study Group to Assess the Effects of Monoclonal Antibody Therapy for Long COVID and COVID-19 Post-Vaccination Syndrome

Invivyd Announces Positive Full Phase 1/2 Clinical Data for VYD2311, a Next Generation COVID-19 Monoclonal Antibody for Potential Use as a Non-Vaccine Preventative and for Treatment of Active Infection

Jun 26, 2025, 7:01 AM EDT - 11 months ago

Invivyd Announces Positive Full Phase 1/2 Clinical Data for VYD2311, a Next Generation COVID-19 Monoclonal Antibody for Potential Use as a Non-Vaccine Preventative and for Treatment of Active Infection

Invivyd Announces Publication of Landmark CANOPY Phase 3 PEMGARDA® (pemivibart) Clinical Trial; Results Underscore Strong Efficacy of Monoclonal Antibodies in Preventing COVID-19 in a Modern U.S. Population Against Relevant, Immune-Evasive SARS-CoV-2 Virus

May 27, 2025, 7:01 AM EDT - 1 year ago

Invivyd Announces Publication of Landmark CANOPY Phase 3 PEMGARDA® (pemivibart) Clinical Trial; Results Underscore Strong Efficacy of Monoclonal Antibodies in Preventing COVID-19 in a Modern U.S. Population Against Relevant, Immune-Evasive SARS-CoV-2 Virus

Invivyd Announces Inclusion of PEMGARDA® (pemivibart) in National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for B-Cell Lymphomas

May 23, 2025, 7:01 AM EDT - 1 year ago

Invivyd Announces Inclusion of PEMGARDA® (pemivibart) in National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for B-Cell Lymphomas

Invivyd Commends FDA Focus on Contemporary Evidence In Evaluating Medical Interventions To Prevent COVID-19

May 21, 2025, 9:30 AM EDT - 1 year ago

Invivyd Commends FDA Focus on Contemporary Evidence In Evaluating Medical Interventions To Prevent COVID-19

Invivyd Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

May 20, 2025, 11:00 AM EDT - 1 year ago

Invivyd Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

Invivyd Earnings Call Transcript: Q1 2025

May 15, 2025, 8:30 AM EDT - 1 year ago

Invivyd Earnings Call Transcript: Q1 2025

Invivyd Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 15, 2025, 7:01 AM EDT - 1 year ago

Invivyd Reports First Quarter 2025 Financial Results and Recent Business Highlights

Invivyd Files Citizen Petition Urging FDA to Focus on Monoclonal Antibodies For Endemic-Virus-Era COVID-19 Prevention, and to Re-Assess COVID-19 Vaccine Efficacy

May 14, 2025, 7:01 AM EDT - 1 year ago

Invivyd Files Citizen Petition Urging FDA to Focus on Monoclonal Antibodies For Endemic-Virus-Era COVID-19 Prevention, and to Re-Assess COVID-19 Vaccine Efficacy

Invivyd to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference

May 13, 2025, 7:01 AM EDT - 1 year ago

Invivyd to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference

Invivyd Announces New Pipeline Discovery Program Focused on Monoclonal Antibody Treatment for Measles

May 12, 2025, 7:01 AM EDT - 1 year ago

Invivyd Announces New Pipeline Discovery Program Focused on Monoclonal Antibody Treatment for Measles

Invivyd to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025

May 8, 2025, 7:01 AM EDT - 1 year ago

Invivyd to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025

Invivyd Announces $30M Non-dilutive Loan Facility with Silicon Valley Bank

Apr 21, 2025, 7:01 AM EDT - 1 year ago

Invivyd Announces $30M Non-dilutive Loan Facility with Silicon Valley Bank

Invivyd Appoints Ajay Royan, Founder of Mithril Capital, to its Board of Directors

Mar 26, 2025, 4:15 PM EDT - 1 year ago

Invivyd Appoints Ajay Royan, Founder of Mithril Capital, to its Board of Directors

Invivyd Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Recent Business Highlights

Mar 20, 2025, 8:01 AM EDT - 1 year ago

Invivyd Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Recent Business Highlights

Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Currently Dominant SARS-CoV-2 Variant LP.8.1

Mar 5, 2025, 7:05 AM EST - 1 year ago

Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Currently Dominant SARS-CoV-2 Variant LP.8.1

FDA Rejects Invivyd's Request To Expand Emergency Authorization For Preventive COVID-19 Antibody For Immunocompromised Patients

Feb 24, 2025, 9:20 AM EST - 1 year ago

FDA Rejects Invivyd's Request To Expand Emergency Authorization For Preventive COVID-19 Antibody For Immunocompromised Patients

FDA Declined Invivyd's Request to Expand Existing Emergency Use Authorization of PEMGARDA™ (pemivibart) to Include Treatment of Mild-to-Moderate COVID-19 For Immunocompromised Persons Who Have No Alternative Therapeutic Options; No Change to the Existing PEMGARDA EUA for Pre-Exposure Prophylaxis of COVID-19 in Certain Immunocompromised Patients

Feb 24, 2025, 7:05 AM EST - 1 year ago

FDA Declined Invivyd's Request to Expand Existing Emergency Use Authorization of PEMGARDA™ (pemivibart) to Include Treatment of Mild-to-Moderate COVID-19 For Immunocompromised Persons Who Have No Alternative Therapeutic Options; No Change to the Existing PEMGARDA EUA for Pre-Exposure Prophylaxis of COVID-19 in Certain Immunocompromised Patients

Invivyd Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025

Feb 12, 2025, 1:20 PM EST - 1 year ago

Invivyd Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025

Invivyd Earnings Call Transcript: Q3 2024

Nov 14, 2024, 8:30 AM EST - 1 year ago

Invivyd Earnings Call Transcript: Q3 2024

Invivyd Transcript: Guggenheim Securities Inaugural Healthcare Innovation Conference

Nov 13, 2024, 2:30 PM EST - 1 year ago

Invivyd Transcript: Guggenheim Securities Inaugural Healthcare Innovation Conference

Invivyd Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 18, 2024, 10:55 AM EDT - 1 year ago

Invivyd Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Invivyd Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Sep 9, 2024, 9:30 AM EDT - 1 year ago

Invivyd Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Invivyd Transcript: Morgan Stanley 22nd Annual Global Healthcare Conference

Sep 6, 2024, 10:00 AM EDT - 1 year ago

Invivyd Transcript: Morgan Stanley 22nd Annual Global Healthcare Conference

Invivyd Earnings Call Transcript: Q2 2024

Aug 14, 2024, 8:30 AM EDT - 1 year ago

Invivyd Earnings Call Transcript: Q2 2024

Invivyd Transcript: Jefferies 2024 Global Healthcare Conference

Jun 6, 2024, 3:00 PM EDT - 2 years ago

Invivyd Transcript: Jefferies 2024 Global Healthcare Conference

Invivyd Transcript: H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

May 20, 2024, 3:00 PM EDT - 2 years ago

Invivyd Transcript: H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

Invivyd Earnings Call Transcript: Q1 2024

May 9, 2024, 4:30 PM EDT - 2 years ago

Invivyd Earnings Call Transcript: Q1 2024

Invivyd Transcript: Status Update

Apr 4, 2024, 5:00 PM EDT - 2 years ago

Invivyd Transcript: Status Update

Invivyd Transcript: FDA Announcement

Mar 22, 2024, 4:00 PM EDT - 2 years ago

Invivyd Transcript: FDA Announcement

Invivyd Transcript: Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference

Feb 8, 2024, 1:00 PM EST - 2 years ago

Invivyd Transcript: Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference

Invivyd Earnings Call Transcript: Q3 2023

Nov 9, 2023, 4:30 PM EST - 2 years ago

Invivyd Earnings Call Transcript: Q3 2023

Invivyd Transcript: Morgan Stanley 21st Global Healthcare Conference

Sep 13, 2023, 12:55 PM EDT - 2 years ago

Invivyd Transcript: Morgan Stanley 21st Global Healthcare Conference

Invivyd Earnings Call Transcript: Q2 2023

Aug 10, 2023, 4:30 PM EDT - 2 years ago

Invivyd Earnings Call Transcript: Q2 2023

Invivyd Transcript: Jefferies 2023 Global Healthcare Conference

Jun 9, 2023, 11:30 AM EDT - 3 years ago

Invivyd Transcript: Jefferies 2023 Global Healthcare Conference

Invivyd Earnings Call Transcript: Q1 2023

May 11, 2023, 4:30 PM EDT - 3 years ago

Invivyd Earnings Call Transcript: Q1 2023

Invivyd Transcript: H.C. Wainwright BioConnect Investor Conference

May 2, 2023, 4:00 PM EDT - 3 years ago

Invivyd Transcript: H.C. Wainwright BioConnect Investor Conference

Invivyd Earnings Call Transcript: Q4 2022

Mar 23, 2023, 4:30 PM EDT - 3 years ago

Invivyd Earnings Call Transcript: Q4 2022

Invivyd Earnings Call Transcript: Q3 2022

Nov 10, 2022, 4:30 PM EST - 3 years ago

Invivyd Earnings Call Transcript: Q3 2022

trader2sde
trader2sde Apr. 30 at 9:38 AM
$IVVD https://nypost.com/2026/04/29/opinion/miranda-devine-the-biden-admins-covid-vaccine-cover-up-and-lies-can-no-longer-be-denied-or-the-damage-it-caused/
0 · Reply
trader2sde
trader2sde Apr. 30 at 9:34 AM
$IVVD
0 · Reply
Stonky_Mcprofitface
Stonky_Mcprofitface Apr. 30 at 12:40 AM
$IVVD *cough*
1 · Reply
trader2sde
trader2sde Apr. 29 at 4:32 AM
$IVVD
0 · Reply
trader2sde
trader2sde Apr. 29 at 4:30 AM
$IVVD https://nypost.com/2026/04/28/us-news/pressure-on-doj-to-prosecute-anthony-fauci-grows-after-adviser-indictedwith-days-left-to-charge-covid-lies/
0 · Reply
trader2sde
trader2sde Apr. 28 at 5:17 PM
$IVVD https://www.cdc.gov/cfa-qualitative-assessments/php/data-research/season-outlook25-26.html
0 · Reply
trader2sde
trader2sde Apr. 28 at 5:04 PM
$IVVD when will FAUCI (pre pardoned by sleepy Joe) be behind bars?? https://www.zerohedge.com/covid-19/top-fauci-advisor-david-morens-charged-covid-records-cover-doj FDA should have gone MABS vs vaccines....
0 · Reply
trader2sde
trader2sde Apr. 28 at 1:59 PM
$IVVD
0 · Reply
trader2sde
trader2sde Apr. 28 at 1:58 PM
$IVVD https://www.medscape.com/viewarticle/long-covid-linked-brain-changes-cognitive-decline-2026a1000dhe?form=fpf
0 · Reply
trader2sde
trader2sde Apr. 28 at 1:57 PM
$IVVD
0 · Reply
JesusIsKing1
JesusIsKing1 Apr. 28 at 9:37 AM
$IVVD Added. Lots of recent institutional buying, add me to the buyers list 🤫
0 · Reply
trader2sde
trader2sde Apr. 27 at 3:42 PM
$IVVD
0 · Reply
NotHopeJustFacts
NotHopeJustFacts Apr. 27 at 1:51 PM
$IVVD covid is so yesterday... who's gonna buy their monoclonal BS if succesful trial ?
1 · Reply
Stonky_Mcprofitface
Stonky_Mcprofitface Apr. 24 at 2:34 PM
$IVVD Be careful here.
0 · Reply
BioStick123
BioStick123 Apr. 24 at 1:48 PM
$IVVD melting down on no volume / catalyst a few months away. This one is a hold / buy at this price. Big fall coming.
0 · Reply
alexx013
alexx013 Apr. 23 at 5:57 PM
$IVVD added @ 1.49
1 · Reply
gb2017384
gb2017384 Apr. 22 at 9:23 PM
$IVVD ,THANK YOU , IVVD YOUR SO GENEROUS $$$$$$!
0 · Reply
trader2sde
trader2sde Apr. 22 at 8:03 PM
$IVVD REMINDER....
0 · Reply
trader2sde
trader2sde Apr. 22 at 8:00 PM
$IVVD OZ and CUBAN at that conference.... mmhh...
0 · Reply
trader2sde
trader2sde Apr. 22 at 7:58 PM
$IVVD MMMHH....
0 · Reply
Quantum_Capital_LLC
Quantum_Capital_LLC Apr. 22 at 6:58 PM
$ATAI $GYRE $IVVD $KZIA $UNCY ATAI made a move, now KZIA is making a move. UNCY is doing alright but GYRE and IVVD seem to have reversed course. GL to all.
0 · Reply
trader2sde
trader2sde Apr. 22 at 2:55 AM
$IVVD
0 · Reply